Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib

Medicine & Life Sciences

• P-selectin ligand protein 95%
• Antibodies, Monoclonal, Humanized 77%
• Bortezomib 73%
• P-Selectin 72%
• Multiple Myeloma 59%
• Cell- and Tissue-Based Therapy 11%
• Bone Marrow 8%
• Stromal Cells 6%
• Plasma Cells 5%
• Neoplasms 5%
• Pharmacokinetics 4%
• Endothelial Cells 4%
• Monoclonal Antibodies 4%
• Cell Proliferation 3%
• Recurrence 3%
• Growth 3%
• Therapeutics 1%

Chemical Compounds

• Bortezomib 100%
• Glycoprotein 55%
• Pharmacokinetics 5%
• Plasma 4%